Novartis Ag

Irm LLC

The Scripps Research Institute

Euroscreen S.a.

Novartis Pharma Gmbh

Carsten Spanka

Niko Schmiedeberg

Pascal Furet

Joseph Schoepfer

Klaus Hinterding

Frédéric Zecri

Nathanael Schiander Gray

Yi Liu

Paul William Manley

Guido Bold

Marc Lang

Giorgio Caravatti

Vito Guagnano

Werner Breitenstein

Tetsuo Uno

Qiang Ding

Clive McCarthy

Guobao Zhang

Bing Li

Gebhard Thoma

Oliver Simic

Neil John Press

Edgar Jacoby

Wolfgang Miltz

Taebo Sim

Weijun Shen

Marie-Odile Roy

Frédéric Stauffer

Carole Pissot Soldermann

Silvio Roggo

David Carcache

Andreas Kordikowski

David William Porter

Juergen Reinhardt

Till Roehn

Peter Buehlmayer

Richard Heng

Wei Li

Christian Markert

Francois Gessier

Sebastien Hannedouche

Andreas Katopodis

Birgit Uta Baumgarten

Rocco Falchetto

Danilo Guerini

Klaus Peter Seuwen

Melanie Stang

Richard Knochenmuss

Andreas Sailer

Juan Zhang

Sophie Noel

Yu Chen

Charles Y Cho

Florian Gruber

Martin Gunzenhauser

Francesca Perruccio

Tian Xie

Yugang Liu

Rainer Martin Lüönd

The present disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein Rthrough Rare as defined herein, and methods of making and using the same.

Compounds and compositions for treating conditions associated with cGAS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Heteroaryl aminopropanol derivatives

The invention relates to compound of the formula (I') or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

Naphthyridinedione derivatives

The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it. 

Pyridopyrimidinedione derivatives

The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it. 

Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones

The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).

3-Methyl-imidazo[1,2-b]pyridazine derivatives

The invention relates to compounds of formula (I) wherein the substituents X, R, R, Rand Rhave the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

Compounds and compositions as protein kinase inhibitors

The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7,25-dihydroxycholesterol) ('7,25DHC') and/or cholest-5-ene-3b, 7b-diol (7-hydroxycholesterol) ('7HC'). The modulator maybe a small chemical molecule, antibody or other therapeutic protein. Methods of medical treatment and methods of identifying modulators are also described.

Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands

Compounds of formula (I) wherein R, R, R, R, R, R, R, X, Y and n are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator

Compounds of formula I wherein R, R, R, Rand Rare as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

Amino-propanol derivatives

Growing community of inventors

Lorrach, Germany

Carsten Spanka